- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02462850
A Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip
A Phase 3 Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip
Study Overview
Detailed Description
The purpose of CLCT-006, a multi-center open-label study, is to evaluate the safety of CL-108 (hydrocodone 7.5 mg/APAP 325 mg, promethazine 12.5 mg) for the treatment of moderate to severe acute pain ("flare") associated with osteoarthritis of the knee or hip under actual conditions of use.
The study will also endeavor to determine
- the physicians' global evaluation of CL-108 as a treatment for moderate to severe acute pain associated with osteoarthritis of the knee or hip
- the patients' global impression of change in pain after treatment of moderate to severe acute pain associated with osteoarthritis of the knee or hip
- any change in the patient's quality of life after treatment of moderate to severe acute pain associated with osteoarthritis of the knee or hip
- the percentage change in pain intensity after treatment of moderate to severe acute pain associated with osteoarthritis of the knee or hip
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA
Informed consent
- Signed consent obtained at screening prior to any procedures being performed.
Gender
- Male or non-pregnant and non-lactating female. A female of child-bearing potential is eligible to participate in this study if she has a negative urine pregnancy test and is post-menopausal or using an acceptable method of birth control (i.e., hormonal, transdermal, or implanted contraceptives, intra-uterine device, diaphragm, condom, abstinence, or surgical sterilization)
Age
- At least 18 years of age
Diagnosis of OA
- Clinical diagnosis of osteoarthritis of the hip and/or knee (signal joints) based on history and physical findings
Confirmation of OA
- Radiographic evidence of OA of the knee or hip (e.g., joint space narrowing, K-L grades 1-4). [Any X-ray finding or report of an X-ray finding at any time that is indicative of OA of the knee or hip confirms the diagnosis of OA.]
Treatment of OA
- Inadequate or unsatisfactory treatment with an NSAID for OA of the knee or hip with no previous use of an opioid for OA (i.e., need for "step up" to opioid treatment).
Flare of OA
- Complaint of acute pain in the knee or hip (i.e., "flare" of osteoarthritis of the knee or hip)
Duration of Acute Pain
- Pain in the signal joint(s) with onset ≤ 14 days
Pain Severity
- Baseline PIS score must be ≥ moderate
Alcohol Intake
- Willing to limit alcohol intake to ≤ 2 drinks per day during the study (i.e., from Screening Visit 1 through Follow-Up Visit 3)
Diary Completion
- Be willing and able to record effectiveness, tolerability, and drug utilization information in the In-Clinic and Outpatient Diaries.
EXCLUSION CRITERIA
Medical Condition
- Presence of a serious uncontrolled medical condition (e.g., poorly controlled hypertension or diabetes)
Confounding Diseases
- Presence of other major joint or bone disease (e.g., gout, inflammatory arthritis, Paget's disease), chronic pain syndrome, or fibromyalgia
Surgery
- Patients who have had surgery on the affected joint within the past 6 months, subjects with a prosthesis at the index joint, patients possibly requiring knee or hip arthroplasty or other surgical procedure on the index joint within 3 months following screening
Drug Allergy
- History of hypersensitivity to an opioid drug, promethazine, acetaminophen, or NSAID (such as ibuprofen) or history of a dystonic/dyskinetic reaction to prior antiemetic or anti-psychotic medication
Confounding and Contraindicated Drugs
- Use within 24 hours of Visit 2 of any analgesic (in particular, opioid), anti-emetic, glucosamine, chondroitin sulfate, or any drug contraindicated with hydrocodone, acetaminophen, or promethazine. Use within 4 months of Visit 2 of any intra-articular or oral corticosteroid or hyaluronic acid.
Investigational Drug Use
- Use of any investigational drug within the past 30 days
Participated in Study
- Previous participation in this study
Pregnancy, Lactation
- Women who are pregnant or breast-feeding
Participant Relationship
- Employee of the Principal Investigator, Sub-investigators or Charleston Laboratories or relative of an employee who is directly involved in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CL-108
CL-108 Hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The safety of CL-108 will be evaluated and assessed by questionnaire, when used, for the treatment of moderate to severe acute pain associated with osteoarthritis of the knee or hip.
Time Frame: 24 hours
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
An assessment of the study medication will be provided as a treatment for osteoarthritis on the Physician's Global Evaluation (PGE) utilizing a poor to excellent scale
Time Frame: 24 hours
|
24 hours
|
The change in arthritic pain since taking study medication over a specific period will be assessed on the Patient Global Impression of Change scale (PGIC)
Time Frame: 24 hours
|
24 hours
|
Patients will complete a standard QOL questionnaire, comprising five dimensions of health-related quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/ depression).
Time Frame: 24 hours
|
24 hours
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLCT-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
Clinical Trials on CL-108
-
Charleston Laboratories, IncCompleted
-
Dow Pharmaceutical SciencesCompleted
-
University of California, San FranciscoCompletedProgressive Supranuclear Palsy | Corticobasal Degeneration Syndrome | Progressive Nonfluent Aphasia | Predicted Tauopathies, Including | Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17United States
-
SRI InternationalTaiho Pharmaceutical Co., Ltd.CompletedBreast CancerUnited States
-
University of California, Los AngelesMassachusetts General Hospital; Washington University School of Medicine; University... and other collaboratorsCompleted
-
Allon TherapeuticsCompletedMild Cognitive Impairment, So StatedUnited States
-
Dow Pharmaceutical SciencesCompletedOnychomycosisUnited States, Canada
-
Immune-Onc TherapeuticsRegeneron PharmaceuticalsActive, not recruiting
-
The First Affiliated Hospital with Nanjing Medical...Guangzhou Lupeng Pharmaceutical Company LTD.; Newave Pharmaceutical IncRecruitingChronic Lymphocytic Leukemia | Non-Hodgkin LymphomaChina
-
Immune-Onc TherapeuticsRecruitingAdvanced Solid TumorChina